AICDA and B-cell chronic lymphocytic leukemia: Notably, none of the patients in this study acquired these mutations (Figure 1B) despite an increased AID-dependent mutational rate, consistent with the low BTK mutation frequency in the CLL setting after ibrutinib treatment (3% in stable disease and 30% in progression, respectively [23]).